BCL2 and B-cell chronic lymphocytic leukemia: We used the functional precision medicine BH3 profiling technique to identify the BCL-2 inhibitor venetoclax as a promising partner for SRF231 in malignant lymphoid cells that depend on BCL-2 for survival, such as CLL cells [27], though our findings are likely to be applicable also to other drugs that selectively inhibit these targets.